NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a
clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the pricing of an underwritten
public offering of 3,700,000 shares of its common stock at a price of $14.00 per share, with expected gross proceeds to Stemline of
$51.8 million. In addition, Stemline has granted the underwriters a 30-day option to purchase up to 555,000 additional shares of
its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on
January 26, 2018, subject to customary closing conditions.
J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Ladenburg
Thalmann & Co. Inc. and H.C. Wainwright & Co. are acting as co-lead managers and Roth Capital Partners, Joseph Gunnar & Co., LLC,
Aegis Capital Corp. and National Securities Corporation are acting as co-managers for the offering.
Stemline intends to use the net proceeds from this offering for (i) clinical, regulatory, manufacturing and, if and when
approved, potential commercial activities of SL‑401; (ii) clinical development of SL‑801 and SL‑701; (iii) research and development
activities; (iv) potential acquisitions and in-licensing; and (v) other general corporate purposes.
Stemline has filed a preliminary prospectus supplement to its shelf registration statement on Form S-3 (File No. 333-219794)
with the U.S. Securities and Exchange Commission (“SEC”) for the public offering of its common stock. The preliminary prospectus
supplement is available on the SEC's web site at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating
to these securities may also be obtained, when available, by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Telephone: (866) 803-9204, or Cowen and Company, LLC, c/o Broadridge
Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department or by telephone at (631)
274-2806.
The offering of these securities is being made under an effective shelf registration statement on file with the SEC. This press
release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.
About Stemline Therapeutics
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics. Stemline is
developing three clinical stage product candidates, SL-401, SL-801, and SL-701. SL-401 is a targeted therapy directed to the
interleukin-3 receptor (CD123) present on a wide range of malignancies. SL-401 has completed a pivotal trial in blastic
plasmacytoid dendritic cell neoplasm (BPDCN), for which it was granted breakthrough therapy designation (BTD). SL-801 is a novel
oral small molecule reversible inhibitor of XPO1 that is currently in a Phase 1 trial of patients with advanced solid tumors.
SL-701, an immunotherapeutic, has completed a Phase 2 trial in patients with second-line glioblastoma and patients are being
followed for long-term outcomes.
Forward-Looking Statements
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include:
statements regarding the public offering and the intended use of proceeds from the offering; the success and timing of our clinical
trials and preclinical studies for our product candidates, including site initiation, institutional review board approval,
scientific review committee approval, patient accrual, safety, tolerability and efficacy data observed, and input from regulatory
authorities including the risk that the FDA or other ex-U.S. national drug authority ultimately does not agree with our
data, find our data supportive of approval, or approve any of our product candidates; our plans to develop and commercialize
our product candidates; market acceptance of our products; reimbursement available for our products; our available cash and
investments; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to obtain
and maintain intellectual property protection for our product candidates; our ability to manufacture; the performance of
third-party manufacturers, clinical research organizations, clinical trial sponsors and clinical trial investigators; and other
risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking
statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these
forward-looking statements to reflect events or circumstances that occur after the date hereof.
Contact
Investor Relations
Stemline Therapeutics, Inc.
750 Lexington Avenue
Eleventh Floor
New York, NY 10022
Tel: 646-502-2307
Email: investorrelations@stemline.com
